本维莫德治疗特应性皮炎及银屑病作用机制的研究进展

doi:10.5246/jcps.2022.12.076

摘要/Abstract

摘要：

特应性皮炎(atopic dermatitis, AD)和银屑病是常见的慢性、复发性、炎症性皮肤病。Th2和Th17细胞介导的细胞免疫分别被认为是AD和银屑病发病机制中必不可少的环节。本维莫德是一种芪类小分子化合物, 自从1965年被发现至今, 已成为国家一类新药, 在临床上用于成人轻中度银屑病的治疗。临床研究表明, 本维莫德对特应性皮炎也有积极的治疗作用。尽管目前对本维莫德作用机制的研究还处于探索阶段, 但是越来越多的证据显示, 本维莫德对皮肤中的芳香烃受体(aryl hydrocarbon receptor, AhR)和核转录因子Nrf2起着重要的调控作用。近年来发现本维莫德调节相关免疫因子的同时, 也广泛参与皮肤微环境中抗氧化途径的激活与皮肤屏障的修复。本文就本维莫德治疗AD和银屑病作用机制的相关研究进展做综述。

关键词: 本维莫德, 特应性皮炎, 银屑病, Tapinarof, AhR, Nrf2

Abstract:

Atopic dermatitis (AD) and psoriasis are common chronic and relapsing inflammatory skin diseases mainly mediated by T cells. Type 2 and 17 inflammations are essential in the pathogenesis of AD and psoriasis, respectively. Clinical evidence suggests that benvitimod, a natural metabolite produced by bacterial symbionts, plays a therapeutic role in the development and progression of both AD and psoriasis. Mechanistically, the two most potent interactions with benvitimod are observed in the aryl hydrocarbon receptor (AhR) and nuclear factor-erythroid 2-related factor-2 (Nrf2) pathways. However, it remains largely unknown how is the local interplay among benvitimod, AhR, and Nrf2, and how the epithelial microenvironment contributes to the complex inflammatory context that results in the treatment of AD and psoriasis. In the present study, the modulatory effects of benvitimod on treating AD and psoriasis.

Key words: Benvitimod, Atopic dermatitis, Psoriasis, Tapinarof, AhR, Nrf2

Supporting:

胡金, 薛佳俊, 申娟. 本维莫德治疗特应性皮炎及银屑病作用机制的研究进展[J]. 中国药学(英文版), 2022, 31(12): 901-911.

Jin Hu, Jiajun Xue, Juan Shen. Possible mechanism of benvitimod in atopic dermatitis and psoriasis[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(12): 901-911.

参考文献 82

[1]	Matejuk, A. Skin immunity. Arch. Immunol. Ther. Exp. (Warsz) 2018, 66, 45–54.
[2]	Orsmond, A.; Bereza-Malcolm, L.; Lynch, T.; March, L.; Xue, M.L. Skin barrier dysregulation in psoriasis. Int. J. Mol. Sci. 2021, 22, 10841.
[3]	Dainichi, T.; Kitoh, A.; Otsuka, A.; Nakajima, S.; Nomura, T.; Kaplan, D.H.; Kabashima, K. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat. Immunol. 2018, 19, 1286–1298.
[4]	Uttarkar, S.; Brembilla, N.C.; Boehncke, W.H. Regulatory cells in the skin: Pathophysiologic role and potential targets for anti-inflammatory therapies. J. Allergy Clin. Immunol. 2019, 143, 1302–1310.
[5]	von Meyenn, L.; Bertschi, N.L.; Schlapbach, C. Targeting T cell metabolism in inflammatory skin disease. Front. Immunol. 2019, 10, 2285.
[6]	Xu, Y.P.; Dimitrion, P.; Cvetkovski, S.; Zhou, L.; Mi, Q.S. Epidermal resident γδ T cell development and function in skin. Cell Mol. Life Sci. 2021, 78, 573–580.
[7]	Afonina, I.S.; Van Nuffel, E.; Beyaert, R. Immune responses and therapeutic options in psoriasis. Cell Mol. Life Sci. 2021, 78, 2709–2727.
[8]	Nakahara, T.; Kido-Nakahara, M.; Tsuji, G.; Furue, M. Basics and recent advances in the pathophysiology of atopic dermatitis. J. Dermatol. 2021, 48, 130–139.
[9]	Nussbaum, L.; Chen, Y.L.; Ogg, G.S. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br. J. Dermatol. 2021, 184, 14–24.
[10]	Dubin, C.; Del Duca, E.; Guttman-Yassky, E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev. Clin. Immunol. 2021, 17, 835–852.
[11]	Paller, A.S.; Kong, H.H.; Seed, P.; Naik, S.; Scharschmidt, T.C.; Gallo, R.L.; Luger, T.; Irvine, A.D. The microbiome in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2019, 143, 26–35.
[12]	Lewis, D.J.; Chan, W.H.; Hinojosa, T.; Hsu, S.; Feldman, S.R. Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: a review. Clin. Dermatol. 2019, 37, 160–166.
[13]	Schäbitz, A.; Eyerich, K.; Garzorz-Stark, N. So close, and yet so far away: the dichotomy of the specific immune response and inflammation in psoriasis and atopic dermatitis. J. Intern. Med. 2021, 290, 27–39.
[14]	Suga, H.; Sato, S. Novel topical and systemic therapies in atopic dermatitis. Immunol. Med. 2019, 42, 84–93.
[15]	Maul, J.T.; Anzengruber, F.; Conrad, C.; Cozzio, A.; Häusermann, P.; Jalili, A.; Kolios, A.G.A.; Laffitte, E.; Lapointe, A.K.; Mainetti, C.; Schlapbach, C.; Trüeb, R.; Yawalkar, N.; Dippel, M.; Navarini, A.A. Topical treatment of psoriasis vulgaris: the Swiss treatment pathway. Dermatology. 2021, 237, 166–178.
[16]	Li, J.; Chen, G.; Wu, H.; Webster, J.M. Identification of two pigments and a hydroxystilbene antibiotic from Photorhabdus luminescens. Appl. Environ. Microbiol. 1995, 61, 4329–4333.
[17]	Cai, L.; Chen, G.H.; Lu, Q.J.; Zheng, M.; Li, Y.Z.; Chen, J.; Zheng, J.; Zhang, F.R.; Yu, J.B.; Yang, S.; Li, F.Q.; Xiao, S.X.; Sun, Q.N.; Xu, J.H.; Gao, X.H.; Fang, H.; Gao, T.W.; Hao, F.; Liu, Q.Z.; Tu, Y.T.; Li, R.Y.; Wang, B.X.; Deng, D.Q.; Zheng, Q.S.; Liu, H.X.; Zhang, J.Z. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin. Med. J. (Engl) 2020, 133, 2905–2909.
[18]	Lebwohl, M.G.; Stein Gold, L.; Strober, B.; Papp, K.A.; Armstrong, A.W.; Bagel, J.; Kircik, L.; Ehst, B.; Hong, H.C.H.; Soung, J.; Fromowitz, J.; Guenthner, S.; Piscitelli, S.C.; Rubenstein, D.S.; Brown, P.M.; Tallman, A.M.; Bissonnette, R. Phase 3 trials of tapinarof cream for plaque psoriasis. N. Engl. J. Med. 2021, 385, 2219–2229.
[19]	Peppers, J.; Paller, A.S.; Maeda-Chubachi, T.; Wu, S.; Robbins, K.; Gallagher, K.; Kraus, J.E. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J. Am. Acad. Dermatol. 2019, 80, 89–98.e3.
[20]	Smith, S.H.; Jayawickreme, C.; Rickard, D.J.; Nicodeme, E.; Bui, T.; Simmons, C.; Coquery, C.M.; Neil, J.; Pryor, W.M.; Mayhew, D.; Rajpal, D.K.; Creech, K.; Furst, S.; Lee, J.; Wu, D.L.; Rastinejad, F.; Willson, T.M.; Viviani, F.; Cote-Sierra, J. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J. Investig. Dermatol. 2017, 137, 2110–2119.
[21]	van den Bogaard, E.H.; Esser, C.; Perdew, G.H. The aryl hydrocarbon receptor at the forefront of host-microbe interactions in the skin: a perspective on current knowledge gaps and directions for future research and therapeutic applications. Exp. Dermatol. 2021, 30, 1477–1483.
[22]	Fernández-Gallego, N.; Sánchez-Madrid, F.; Cibrian, D. Role of AHR ligands in skin homeostasis and cutaneous inflammation. Cells. 2021, 10, 3176.
[23]	Kim, J.; Park, S.H.; Seyoung, Y.; Oh, S.; Kwon, K.; Park, S.; Yu, E.; Kim, H.; Park, J.; Choi, S.; Yang, S.; Song, M.; Cho, J.; Lee, J. Protective effects of maclurin against benzo[a]pyrene via aryl hydrocarbon receptor and nuclear factor erythroid 2-related factor 2 targeting. Antioxidants. 2021, 10, 1189.
[24]	Liu, X.C.; Zhang, X.N.; Zhang, J.X.; Luo, Y.; Xu, B.L.; Ling, S.Q.; Zhang, Y.; Li, W.; Yao, X. Activation of aryl hydrocarbon receptor in Langerhans cells by a microbial metabolite of tryptophan negatively regulates skin inflammation. J. Dermatol. Sci. 2020, 100, 192–200.
[25]	Roztocil, E.; Hammond, C.L.; Gonzalez, M.O.; Feldon, S.E.; Woeller, C.F. The aryl hydrocarbon receptor pathway controls matrix metalloproteinase-1 and collagen levels in human orbital fibroblasts. Sci. Rep. 2020, 10, 8477.
[26]	Wang, X.W.; Li, S.L.; Liu, L.; Jian, Z.; Cui, T.T.; Yang, Y.Q.; Guo, S.; Yi, X.L.; Wang, G.; Li, C.Y.; Gao, T.W.; Li, K. Role of the aryl hydrocarbon receptor signaling pathway in promoting mitochondrial biogenesis against oxidative damage in human melanocytes. J. Dermatol. Sci. 2019, 96, 33–41.
[27]	Tsuji, N.; Fukuda, K.; Nagata, Y.; Okada, H.; Haga, A.; Hatakeyama, S.; Yoshida, S.; Okamoto, T.; Hosaka, M.; Sekine, K.; Ohtaka, K.; Yamamoto, S.; Otaka, M.; Grave, E.; Itoh, H. The activation mechanism of the aryl hydrocarbon receptor (AhR) by molecular chaperone HSP90. FEBS Open Bio. 2014, 4, 796–803.
[28]	Cox, M.B.; Miller, C.A. 3rd. Cooperation of heat shock protein 90 and p23 in aryl hydrocarbon receptor signaling. Cell Stress Chaperones. 2004, 9, 4–20.
[29]	Kazlauskas, A.; Poellinger, L.; Pongratz, I. Evidence that the Co-chaperone p23 regulates ligand responsiveness of the dioxin (aryl hydrocarbon) receptor. J. Biol. Chem. 1999, 274, 13519–13524.
[30]	Backlund, M.; Ingelman-Sundberg, M. Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. Cell Signal. 2005, 17, 39–48.
[31]	Meyer, B.K.; Pray-Grant, M.G.; Vanden Heuvel, J.P.; Perdew, G.H. Hepatitis B virus X-associated protein 2 is a subunit of the unliganded aryl hydrocarbon receptor core complex and exhibits transcriptional enhancer activity. Mol. Cell Biol. 1998, 18, 978–988.
[32]	Reyes, H.; Reisz-Porszasz, S.; Hankinson, O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science. 1992, 256, 1193–1195.
[33]	Nakano, N.; Sakata, N.; Katsu, Y.; Nochise, D.; Sato, E.; Takahashi, Y.; Yamaguchi, S.; Haga, Y.; Ikeno, S.; Motizuki, M.; Sano, K.; Yamasaki, K.; Miyazawa, K.; Itoh, S. Dissociation of the AhR/ARNT complex by TGF-β/Smad signaling represses CYP1A1 gene expression and inhibits benze[a]pyrene-mediated cytotoxicity. J. Biol. Chem. 2020, 295, 9033–9051.
[34]	Ahmed, S.; Wang, A.N.; Celius, T.; Matthews, J. Zinc finger nuclease-mediated knockout of AHR or ARNT in human breast cancer cells abolishes basal and ligand-dependent regulation of CYP1B1 and differentially affects estrogen receptor α transactivation. Toxicol. Sci. 2013, 138, 89–103.
[35]	Swanson, H.I. Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective. Chem. Biol. Interact. 2004, 149, 69–79.
[36]	Vogel, C.F.A.; Van Winkle, L.S.; Esser, C.; Haarmann-Stemmann, T. The aryl hydrocarbon receptor as a target of environmental stressors - Implications for pollution mediated stress and inflammatory responses. Redox Biol. 2020, 34, 101530.
[37]	Yuan, J.W.; Sun, X.M.; Che, S.Y.; Zhang, L.; Ruan, Z.; Li, X.M.; Yang, J.H. AhR-mediated CYP1A1 and ROS overexpression are involved in hepatotoxicity of decabromodiphenyl ether (BDE-209). Toxicol. Lett. 2021, 352, 26–33.
[38]	Cui, H.M.; Gu, X.S.; Chen, J.S.; Xie, Y.; Ke, S.; Wu, J.; Golovko, A.; Morpurgo, B.; Yan, C.H.; Phillips, T.D.; Xie, W.; Luo, J.Y.; Zhou, Z.J.; Tian, Y.N. Pregnane X receptor regulates the AhR/Cyp1A1 pathway and protects liver cells from benzo-[α]-pyrene-induced DNA damage. Toxicol. Lett. 2017, 275, 67–76.
[39]	Nakano, N.; Sakata, N.; Katsu, Y.; Nochise, D.; Sato, E.; Takahashi, Y.; Yamaguchi, S.; Haga, Y.; Ikeno, S.; Motizuki, M.; Sano, K.; Yamasaki, K.; Miyazawa, K.; Itoh, S. Dissociation of the AhR/ARNT complex by TGF-β/Smad signaling represses CYP1A1 gene expression and inhibits benze[a]pyrene-mediated cytotoxicity. J. Biol. Chem. 2020, 295, 9033–9051.
[40]	Tzeng, H.P.; Lan, K.C.; Yang, T.H.; Chung, M.N.; Liu, S.H. Benzo[a]pyrene activates interleukin-6 induction and suppresses nitric oxide-induced apoptosis in rat vascular smooth muscle cells. PLoS One. 2017, 12, e0178063.
[41]	Hu, T.T.; Pan, Z.Y.; Yu, Q.; Mo, X.H.; Song, N.J.; Yan, M.; Zouboulis, C.C.; Xia, L.Q.; Ju, Q. Benzo(a)pyrene induces interleukin (IL)-6 production and reduces lipid synthesis in human SZ95 sebocytes via the aryl hydrocarbon receptor signaling pathway. Environ. Toxicol. Pharmacol. 2016, 43, 54–60.
[42]	Schulz, V.J.; Smit, J.J.; Huijgen, V.; Bol-Schoenmakers, M.; van Roest, M.; Kruijssen, L.J.W.; Fiechter, D.; Hassing, I.; Bleumink, R.; Safe, S.; van Duursen, M.B.M.; van den Berg, M.; Pieters, R.H.H. Non-dioxin-like AhR ligands in a mouse peanut allergy model. Toxicol. Sci. 2012, 128, 92–102.
[43]	Guttman-Yassky, E.; Brunner, P.M.; Neumann, A.U.; Khattri, S.; Pavel, A.B.; Malik, K.; Singer, G.K.; Baum, D.; Gilleaudeau, P.; Sullivan-Whalen, M.; Rose, S.; On, S.J.; Li, X.; Fuentes-Duculan, J.; Estrada, Y.; Garcet, S.; Traidl-Hoffmann, C.; Krueger, J.G.; Lebwohl, M.G. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J. Am. Acad. Dermatol. 2018, 78, 872–881.e6.
[44]	Furue, M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int. J. Mol. Sci. 2020, 21, 5382.
[45]	Murray, I.A.; Patterson, A.D.; Perdew, G.H. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat. Rev. Cancer. 2014, 14, 801–814.
[46]	Kiyomatsu-Oda, M.; Uchi, H.; Morino-Koga, S.; Furue, M. Protective role of 6-formylindolo[3, 2-b]carbazole (FICZ), an endogenous ligand for arylhydrocarbon receptor, in chronic mite-induced dermatitis. J. Dermatol. Sci. 2018, 90, 284–294.
[47]	Furue, M.; Uchi, H.; Mitoma, C.; Hashimoto-Hachiya, A.; Tanaka, Y.; Ito, T.; Tsuji, G. Implications of tryptophan photoproduct FICZ in oxidative stress and terminal differentiation of keratinocytes. G. Ital. Dermatol. Venereol. 2019, 154, 37–41.
[48]	Elentner, A.; Finke, D.; Schmuth, M.; Chappaz, S.; Ebner, S.; Malissen, B.; Kissenpfennig, A.; Romani, N.; Dubrac, S. Langerhans cells are critical in the development of atopic dermatitis-like inflammation and symptoms in mice. J. Cell Mol. Med. 2009, 13, 2658–2672.
[49]	Kado, S.; Chang, W.L.W.; Chi, A.N.; Wolny, M.; Shepherd, D.M.; Vogel, C.F.A. Aryl hydrocarbon receptor signaling modifies Toll-like receptor-regulated responses in human dendritic cells. Arch. Toxicol. 2017, 91, 2209–2221.
[50]	Junttila, I.S. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front. Immunol. 2018, 9, 888.
[51]	Takei, K.; Mitoma, C.; Hashimoto-Hachiya, A.; Uchi, H.; Takahara, M.; Tsuji, G.; Kido-Nakahara, M.; Nakahara, T.; Furue, M. Antioxidant soybean tar Glyteer rescues T-helper-mediated downregulation of filaggrin expression via aryl hydrocarbon receptor. J. Dermatol. 2015, 42, 171–180.
[52]	Takemura, M.; Nakahara, T.; Hashimoto-Hachiya, A.; Furue, M.; Tsuji, G. Glyteer, soybean tar, impairs IL-4/Stat6 signaling in murine bone marrow-derived dendritic cells: the basis of its therapeutic effect on atopic dermatitis. Int. J. Mol. Sci. 2018, 19, 1169.
[53]	Jeong, K.T.; Hwang, S.J.; Oh, G.S.; Park, J.H. FICZ, a Tryptophan photoproduct, suppresses pulmonary eosinophilia and Th2-type cytokine production in a mouse model of ovalbumin-induced allergic asthma. Int. Immunopharmacol. 2012, 13, 377–385.
[54]	Koch, S.; Stroisch, T.J.; Vorac, J.; Herrmann, N.; Leib, N.; Schnautz, S.; Kirins, H.; Förster, I.; Weighardt, H.; Bieber, T. AhR mediates an anti-inflammatory feedback mechanism in human Langerhans cells involving FcεRI and IDO. Allergy. 2017, 72, 1686–1693.
[55]	Fuentes, F.; Gomez, Y.; Paredes-Gonzalez, X.; Barve, A.; Nair, S.; Yu, S.W.; Saw, C.L.L.; Kong, A.N.T. Nrf2-mediated antioxidant and detoxifying enzyme induction by a combination of curcumin and sulforaphaneNrf2-mediated antioxidant and detoxifying enzyme induction by a combination of curcumin and sulforaphane. J. Chin. Pharm. Sci. 2016, 25, 559–569.
[56]	He, F.; Ru, X.L.; Wen, T. NRF2, a transcription factor for stress response and beyond. Int. J. Mol. Sci. 2020, 21, 4777.
[57]	He, L.; Xu, J.L.; Guo, L.M.; Que, L.L.; Yin, W.C.; Cao, B.S.; Yu, S.W. Nrf2/ARE signaling protects against oxaliplatin-induced hepatotoxicity in mice. J. Chin. Pharm. Sci. 2017, 26, 709–718.
[58]	Jain, A.; Lamark, T.; Sjøttem, E.; Bowitz Larsen, K.; Atesoh Awuh, J.; Øvervatn, A.; McMahon, M.; Hayes, J.D.; Johansen, T. p62/SQSTM1 is a target gene for transcription factor NRF₂ and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J. Biol. Chem. 2010, 285, 22576–22591.
[59]	Han, D.D.; Gu, X.L.; Gao, J.; Wang, Z.; Liu, G.; Barkema, H.W.; Han, B. Chlorogenic acid promotes the Nrf2/HO-1 anti-oxidative pathway by activating p21^Waf1/Cip1 to resist dexamethasone-induced apoptosis in osteoblastic cells. Free Radic. Biol. Med. 2019, 137, 1–12.
[60]	Lu, K.; Alcivar, A.L.; Ma, J.L.; Foo, T.K.; Zywea, S.; Mahdi, A.; Huo, Y.Y.; Kensler, T.W.; Gatza, M.L.; Xia, B. NRF₂ induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP₃-KEAP1 interaction. Cancer Res. 2017, 77, 2881–2892.
[61]	Gorrini, C.; Baniasadi, P.S.; Harris, I.S.; Silvester, J.; Inoue, S.; Snow, B.; Joshi, P.A.; Wakeham, A.; Molyneux, S.D.; Martin, B.; Bouwman, P.; Cescon, D.W.; Elia, A.J.; Winterton-Perks, Z.; Cruickshank, J.; Brenner, D.; Tseng, A.; Musgrave, M.; Berman, H.K.; Khokha, R.; Jonkers, J.; Mak, T.W.; Gauthier, M.L. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J. Exp. Med. 2013, 210, 1529–1544.
[62]	Camp, N.D.; James, R.G.; Dawson, D.W.; Yan, F.; Davison, J.M.; Houck, S.A.; Tang, X.B.; Zheng, N.; Major, M.B.; Moon, R.T. Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF₂ protein through competitive binding to KEAP1 protein. J. Biol. Chem. 2012, 287*, 6539–6550.
[63]	Shan, Y.L.; Wei, Z.H.; Tao, L.; Wang, S.L.; Zhang, F.; Shen, C.S.; Wu, H.Y.; Liu, Z.G.; Zhu, P.T.; Wang, A.Y.; Chen, W.X.; Lu, Y. Prophylaxis of diallyl disulfide on skin carcinogenic model via p21-dependent Nrf2 stabilization. Sci. Rep. 2016, 6, 35676.
[64]	Shaw, P.; Chattopadhyay, A. Nrf2-ARE signaling in cellular protection: mechanism of action and the regulatory mechanisms. J. Cell Physiol. 2020, 235, 3119–3130.
[65]	Vasiliou, V.; Puga, A.; Chang, C.Y.; Tabor, M.W.; Nebert, D.W. Interaction between the Ah receptor and proteins binding to the AP-1-like electrophile response element (EpRE) during murine phase II[Ah]battery gene expression. Biochem. Pharmacol. 1995, 50, 2057–2068.
[66]	Miao, W.M.; Hu, L.G.; Scrivens, P.J.; Batist, G. Transcriptional regulation of NF-E2 p45-related factor (NRF₂) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway. J. Biol. Chem. 2005, 280, 20340–20348.
[67]	Chen, G.; Shin, J.A. AhR/Arnt: XRE interaction: turning false negatives into true positives in the modified yeast one-hybrid assay. Anal. Biochem. 2008, 382, 101–106.
[68]	Yang, L.T.; Fan, X.L.; Cui, T.T.; Dang, E.L.; Wang, G. Nrf2 promotes keratinocyte proliferation in psoriasis through up-regulation of keratin 6, keratin 16, and keratin 17. J. Investig. Dermatol. 2017, 137, 2168–2176.
[69]	Lee, Y.; Shin, J.M.; Jang, S.; Choi, D.K.; Seo, M.S.; Kim, H.R.; Sohn, K.C.; Im, M.; Seo, Y.J.; Lee, J.H.; Kim, C.D. Role of nuclear factor E2-related factor 2 (Nrf2) in epidermal differentiation. Arch. Dermatol. Res. 2014, 306, 677–682.
[70]	Kurinna, S.; Muzumdar, S.; Köhler, U.A.; Kockmann, T.; Auf dem Keller, U.; Schäfer, M.; Werner, S. Autocrine and paracrine regulation of keratinocyte proliferation through a novel Nrf2-IL-36γ pathway. J. Immunol. 2016, 196, 4663–4670.
[71]	Yoo, O.K.; Choi, W.J.; Keum, Y.S. Cardamonin inhibits oxazolone-induced atopic dermatitis by the induction of NRF₂ and the inhibition of Th2 cytokine production. Antioxidants. (Basel) 2020, 9, 834.
[72]	Saidu, N.; Kavian, N.; Leroy, K.; Jacob, C.; Nicco, C.; Batteux, F.; Alexandre, J. Dimethyl fumarate, a two-edged drug: Current status and future directions. Med. Res. Rev. 2019, 39, 1923–1952.
[73]	Jiménez-Osorio, A.S.; González-Reyes, S.; Pedraza-Chaverri, J. Natural Nrf2 activators in diabetes. Clin. Chimica Acta. 2015, 448, 182–192.
[74]	Zhang, Q.Y.; Chu, X.Y.; Jiang, L.H.; Liu, M.Y.; Mei, Z.L.; Zhang, H.Y. Identification of non-electrophilic Nrf2 activators from approved drugs. Molecules. 2017, 22, 883.
[75]	Yanaka, A. Contribution of NRF₂ in gastrointestinal protection from oxidative injury. Curr. Pharm. Des. 2018, 24, 2023–2033.
[76]	Singh, R.; Chandrashekharappa, S.; Bodduluri, S.R.; Baby, B.V.; Hegde, B.; Kotla, N.G.; Hiwale, A.A.; Saiyed, T.; Patel, P.; Vijay-Kumar, M.; Langille, M.G.I.; Douglas, G.M.; Cheng, X.; Rouchka, E.C.; Waigel, S.J.; Dryden, G.W.; Alatassi, H.; Zhang, H.G.; Haribabu, B.; Vemula, P.K.; Jala, V.R. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nat. Commun. 2019, 10, 89.
[77]	Koh, L.F.; Ong, R.Y.; Common, J.E. Skin microbiome of atopic dermatitis. Allergol. Int. 2022, 71, 31–39.
[78]	Drago, L.; De Grandi, R.; Altomare, G.; Pigatto, P.; Rossi, O.; Toscano, M. Skin microbiota of first cousins affected by psoriasis and atopic dermatitis. Clin. Mol. Allergy. 2016, 14, 2.
[79]	Smits, J.P.H.; Ederveen, T.H.A.; Rikken, G.; van den Brink, N.J.M.; van Vlijmen-Willems, I.M.J.J.; Boekhorst, J.; Kamsteeg, M.; Schalkwijk, J.; van Hijum, S.A.F.T.; Zeeuwen, P.L.J.M.; van den Bogaard, E.H. Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHR-dependent induction of antimicrobial peptides. J. Investig. Dermatol. 2020, 140, 415–424.e10.
[80]	Uberoi, A.; Bartow-Mckenney, C.; Zheng, Q.; Flowers, L.; Campbell, A.; Knight, S.A.B.; Chan, N.; Wei, M.; Lovins, V.; Bugayev, J.; Horwinski, J.; Bradley, C.; Meyer, J.; Crumrine, D.; Sutter, C.H.; Elias, P.; Mauldin, E.; Sutter, T.R.; Grice, E.A. Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor. Cell Host Microbe. 2021, 29, 1235–1248.e8.
[81]	Armstrong, A.W.; Puig, L.; Joshi, A.; Skup, M.; Williams, D.; Li, J.L.; Betts, K.A.; Augustin, M. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020, 156, 258–269.
[82]	Mendes Roncada, E.V.; Brambilla, V.R.; Freitas Filitto, B.; Genta, M.P.; Morgado de Abreu, M. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis. Case Rep. Dermatol. 2021, 13, 336–339.